Glioblastoma and brain metastasis share many similarities: symptoms, location, and appearance on imaging. However, distinguishing between them is crucial because their treatment approaches are radically different. We explain why this diagnosis is so complex and how advanced MRI helps clinicians gain a clearer understanding.
Glioblastoma and brain metastases: two very different tumors, yet so similar
Glioblastoma (GBM) is the most aggressive and most common primary malignant brain tumor in adults, accounting for 45 to 50% of all malignant brain tumors. It develops from glial cells, which ensure the proper functioning of the central nervous system whose uncontrolled proliferation forms a tumor mass that infiltrates the surrounding brain tissue.
Brain metastases, on the other hand, are secondary tumors: they originate elsewhere in the body (lung, breast, melanoma, etc.) and spread to the brain. Approximately 20% of cancer patients will develop them, making them the third most common neurological condition in terms of incidence. Unlike GBM, they are cellularly similar to the primary tumor from which they originated.
Together, these two conditions account for the most common types of malignant brain tumors in adults. A common factor that complicates the diagnosis.
Symptoms that largely overlap
Clinically, glioblastoma and brain metastases present with very similar symptoms. Patients typically report:
– Persistent headaches
– Focal neurological symptoms: visual, motor, or sensory impairments
– Cognitive or psychiatric disorders
– Signs of increased intracranial pressure: nausea, vomiting
In more than half of cases, both types of tumors are located in the cerebral hemispheres. And on conventional MRI scans, they often look almost identical.
Why is it crucial to distinguish between them?
Despite these similarities, the distinction between glioblastoma and brain metastases is crucial, as their treatment approaches are radically different.
Generally speaking, two factors point toward a diagnosis of metastasis: a known history of cancer and the presence of multiple brain lesions. However, in 40 to 50% of cases, brain metastasis involves a single lesion, making it all the more likely to be mistaken for a GBM. Worse still, it may be the very first manifestation of an as-yet-unknown extracranial cancer.
The choice of treatment, whether radical surgery, chemoradiation, or radiation therapy or chemotherapy alone, depends directly on the type of tumor. As for the prognosis, it varies significantly: the 5-year survival rate is 5 to 7% for glioblastoma, while it varies depending on the origin of the primary tumor for metastases.
MRI: the key test for differential diagnosis
When a brain tumor is suspected, an MRI is the essential imaging test. Following a clinical examination, it can detect lesions as small as a few millimeters and precisely characterize each abnormality: size, number, location, perilesional edema, and mass effect.
Single lesion: when advanced MRI makes the difference
On conventional MRI, both glioblastoma and solitary brain metastases show central necrosis, heterogeneous ring-like enhancement, and peritumoral edema. These classic anatomical features alone are not sufficient to make a definitive diagnosis.
This is where advanced MRI sequences come into play. They enable the assessment of tissue parameters that differ significantly between the two conditions: tumor cell density, the ultrastructure of tumor capillaries, and vascular permeability. These data make differentiation possible, even for a single lesion.
Multiple lesions: a major radiological challenge
The situation becomes much more complex when multiple lesions are present. In such cases, there are no significant radiological differences in FLAIR intensity values or edema size between multifocal GBM and multiple metastases.
However, certain parameters can help guide the diagnosis:
– The size of the tumor lesions
– The distance between the different lesions
– The ADC value of the nearby perilesional edema (≤5 mm)
– The FLAIR signal intensity of the tumor
By combining these parameters, it is possible to reliably distinguish multicentric glioblastomas from multiple brain metastases. However, in some cases, radiological differentiation remains impossible, illustrating the current limitations of imaging alone.
Toward artificial Intelligence for a more accurate diagnosis?
Distinguishing between glioblastoma and brain metastases remains a major diagnostic challenge, particularly in cases involving multiple lesions. A combined analysis of several radiological criteria can guide the clinician, but the number and complexity of these parameters require the expertise of an experienced neuroradiologist.
This issue represents a particularly promising area for artificial intelligence and medical image processing software. Approaches based on deep learning could, in the long term, serve as a powerful complementary tool for improving diagnostic accuracy, thereby enabling patients to be referred more quickly to the appropriate care.
A medical challenge, but also a human one: behind every lesion, a patient is waiting for an accurate diagnosis so they can receive the right treatment.
